IVAX
To see an up-to date selection of historical analyses and insights on
IVAX,
visit our
new, dynamically updated Company Summary report pages for IVAX.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
IVAX are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
IVAX,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| IVAX |
- |
Baclofen |
baclofen |
GABA agonist |
2 |
- |
|
n/a |
|
|
|
- |
Clozapine |
clozapine |
Atypical anti-psychotic |
3 |
- |
|
n/a |
|
|
|
- |
Hydrochlorothiazide |
hydrochlorothiazide |
Thiazide |
2 |
- |
|
n/a |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| IVAX |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
|
|
| Valuing the Enterprise |
| Free Cash Flow (Pre-Dividends) |
244 |
58 |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
2,260 |
188 |
| Cost of Goods Sold |
(1,314) |
(103) |
| S,G & A |
(520) |
(37) |
| R&D |
(136) |
(11) |
| Other Income/ Expense - Net |
0 |
(1) |
| EBIT - Normalised |
291 |
37 |
| Net Interest & Financial Items |
(45) |
(2) |
| Pre-tax Profits - Normalised |
246 |
35 |
| Exceptionals |
(25) |
- |
| Income Before Taxes |
221 |
35 |
| Tax |
(69) |
(10) |
| Tax Rate (%) |
31.4% |
28.5% |
| Minorities |
0 |
0 |
| Net Income - Reported |
152 |
25 |
| Net Income - Normalised |
168 |
25 |
|
|
| Per Share Data |
| EPS - Diluted |
0.55 |
0.09 |
| EPS - Basic |
0.57 |
0.09 |
| EPS - Normalised (diluted) |
0.61 |
0.09 |
| EPS - Normalised (basic) |
0.63 |
0.09 |
| Avg. Shares Outstanding - Diluted |
278.4 |
279.1 |
| Avg. Shares Outstanding - Basic |
268.3 |
269.0 |
| DPS |
0.00 |
- |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| IVAX |
Acetaminophen & codeine phosphate |
acetaminophen & codeine |
|
|
Acyclovir |
acyclovir |
|
|
Adaprolol Maleate |
- |
|
|
Airomir |
albuterol |
|
|
Albuterol/Volare |
albuterol |
|
|
Allay |
acetaminophen & hydrocodone |
|
|
Alprazolam |
alprazolam |
|
|
Amlodipine |
amlodipine besylate |
|
|
Amoxicillin |
amoxicillin |
|
|
Amoxicillin/Clavulanate |
amoxicillin & clavulanate |
|
|
Anagrelide |
anagrelide |
|
|
Baclofen |
baclofen |
|
|
Beclomethasone |
beclomethasone |
|
|
Benazepril Hydrochloride |
benazepril |
|
|
Betaxoxime |
- |
|
|
BiCitra |
sodium citrate & citric acid |
|
|
Brimonidine tartrate |
brimonidine tartrate |
|
|
Budesonide |
budesonide |
|
|
Bumetanide |
bumetanide |
|
|
Buspirone |
buspirone |
|
|
Captopril |
captopril |
|
|
Captopril & hydrochlorothiazide |
captopril & hydrochlorothiazide |
|
|
Cefaclor |
cefaclor |
|
|
Cefadroxil |
cefadroxil |
|
|
Cefuroxime axetil |
cefuroxime axetil |
|
|
Chloramphenicol |
chloramphenicol |
|
|
Chlorthalidone |
chlorthalidone |
|
|
Cholestyramine |
cholestyramine |
|
|
Cilostazol |
cilostazol |
|
|
Cimetidine |
cimetidine |
|
|
Ciprofloxacin |
ciprofloxacin |
|
|
Citalopram |
citalopram |
|
|
Clarithromycin |
clarithromycin |
|
|
Clozapine |
clozapine |
|
|
Cromogen |
cromolyn sodium |
|
|
C-Solve-2 |
erythromycin |
|
|
Cyproheptadine hydrochloride |
cyproheptadine hydrochloride |
|
|
Diazepam |
diazepam |
|
|
Diltiazem hydrochloride |
diltiazem |
|
|
Disopyramide phosphate |
disopyramide |
|
|
Doral |
quazepam |
|
|
Doxazosin mesylate |
doxazosin |
|
|
Doxycycline hyclate |
doxycycline |
|
|
Elmiron |
pentosan polysulfate sodium |
|
|
Enalapril |
enalapril |
|
|
Equoral |
cyclosporin |
|
|
Erectile Dysfunction Compound |
- |
|
|
Erythromycin stearate |
erythromycin stearate |
|
|
Estazolam |
estazolam |
|
|
Etodolac |
etodolac |
|
|
Famotidine |
famotidine |
|
|
Fenoprofen calcium |
fenoprofen |
|
|
Fluconazole |
fluconazole |
|
|
Fluoxetine |
fluoxetine |
|
|
Flurbiprofen |
flurbiprofen |
|
|
Flutamide |
flutamide |
|
|
Flutex |
triamcinolone acetonide |
|
|
Folic acid |
folic acid |
|
|
Foradil Airmax |
formoterol |
|
|
Formoterol |
formoterol |
|
|
Furosemide |
furosemide |
|
|
Gabapentin/Gabaron |
gabapentin |
|
|
Glipizide |
glipizide |
|
|
Glyburide/Metformin HCl |
metformin & glyburide |
|
|
Guanabenz acetate |
guanabenz acetate |
|
|
GYKI 63461 |
- |
|
|
GYKI 63475 |
- |
|
|
GYKI 66319 |
- |
|
|
GYKI 66323 |
- |
|
|
GYKI 66430 |
- |
|
|
Hydrochlorothiazide |
hydrochlorothiazide |
|
|
Hydrocortisone |
hydrocortisone |
|
|
Hydrogenated ergot alkaloids |
ergoloid mesylates |
|
|
Hydroxyzine pamoate |
hydroxyzine |
|
|
Ibuprofen |
ibuprofen |
|
|
Indapamide |
indapamide |
|
|
Indomethacin |
indomethacin |
|
|
Ipratropium bromide |
ipratropium |
|
|
Isosorbide mononitrate |
isosorbide mononitrate |
|
|
Labetalol hydrochloride |
labetalol |
|
|
Lamotrigine |
lamotrigine |
|
|
Levothyroxine sodium |
levothyroxine |
|
|
Lisinopril |
lisinopril |
|
|
Lisinopril & HCTZ |
lisinopril & hydrochlorothiazide |
|
|
Meclizine hydrochloride |
meclizine |
|
|
Metformin |
metformin |
|
|
Metformin ER |
metformin |
|
|
Methocarbamol & aspirin |
methocarbamol & aspirin |
|
|
Methyclothiazide |
methyclothiazide |
|
|
Methyldopa |
methyldopa |
|
|
Metronidazole |
metronidazole |
|
|
Misoprostol |
misoprostol |
|
|
Morphine Sulfate |
morphine sulfate |
|
|
Mucodyne |
carbocisteine |
|
|
Nabumetone |
nabumetone |
|
|
Nadolol |
nadolol |
|
|
Naproxen |
naproxen |
|
|
Nasarel/Nasalide |
flunisolide |
|
|
Nasofan/Fluticasone |
fluticasone propionate |
|
|
Nefazodone |
nefazodone |
|
|
Neutra Phos |
potassium phosphate & sodium phosphate |
|
|
Nicardipine hydrochloride |
nicardipine |
|
|
Nitrofurantoin |
nitrofurantoin |
|
|
Nizatidine |
nizatidine |
|
|
Nogenic HC |
hydrocortisone |
|
|
Omeprazole |
omeprazole |
|
|
Onxol/Paxene |
paclitaxel |
|
|
Oxazepam |
oxazepam |
|
|
Oxycodone |
oxycodone |
|
|
Pergolide |
pergolide mesylate |
|
|
Perphenazine |
perphenazine |
|
|
Pindolol |
pindolol |
|
|
Piroxicam |
piroxicam |
|
|
PolyCitra |
potassium citrate |
|
|
Pravastatin |
pravastatin |
|
|
Prazosin hydrochloride |
prazosin |
|
|
Probenecid |
probenecid |
|
|
Probenecid & colchicine |
probenecid & colchicine |
|
|
Procainamide hydrochloride |
procainamide |
|
|
Prochlorperazine maleate |
prochlorperazine |
|
|
Propoxyphene hydrochloride |
propoxyphene hydrochloride |
|
|
Propoxyphene napsylate & acetaminophen |
propoxyphene napsylate & acetaminophen |
|
|
QVAR |
beclomethasone |
|
|
Ranitidine HCL |
ranitidine |
|
|
rM/NEI |
- |
|
|
Selenium sulfide |
selenium sulfide |
|
|
Sulfinpyrazone |
sulfinpyrazone |
|
|
Sulfisoxazole |
sulfisoxazole |
|
|
Tamoxifen |
tamoxifen |
|
|
Tetracycline hydrochloride |
tetracycline hydrochloride |
|
|
Thioridazine hydrochloride |
thioridazine hydrochloride |
|
|
Tizanidine |
tizanidine |
|
|
Tolazamide |
tolazamide |
|
|
Tolbutamide |
tolbutamide |
|
|
Tolmetin sodium |
tolmetin sodium |
|
|
Tramadol |
tramadol |
|
|
Tramadol & Acetaminophen |
acetaminophen & tramadol |
|
|
Triamterene & hydrochlorothiazide |
triamterene & hydrochlorothiazide |
|
|
Triatex |
triamcinolone acetonide |
|
|
Trifluoperazine hydrochloride |
trifluoperazine |
|
|
Verapamil hydrochloride |
verapamil |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
